Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLL-1-CD70 CAR-T
- Development stage
- Phase 1
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CLL-1-CD70 CAR-T is an investigational autologous, dual-targeted chimeric antigen receptor T-cell (CAR-T) therapy designed to target both C-type lectin-like molecule-1 (CLL-1, also known as CLEC12A) and CD70. Developed by Dr. Liping Dou at the Chinese PLA General Hospital, this therapy is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML). By simultaneously targeting CLL-1 and CD70, which are highly expressed on AML blasts and leukemic stem cells (LSCs) but largely absent on normal hematopoietic stem cells (HSCs), the therapy aims to enhance antileukemic efficacy, prevent antigen escape, and minimize on-target, off-tumor myelosuppression. It is administered as a single intravenous infusion following lymphodepleting conditioning.
- Other names
- CLL-1-CD70 CAR-T Cell InjectionCLL1-CD70 CAR-T Cell InjectionCLL 1-CD70 CAR-T Cell InjectionCLL-1/CD70 CAR-TCLL-1/CD70 CAR-T Cell InjectionCLL-1/CD70 dual-target CAR-T cell injection
02
Targets
TNFRSF9 (CD137 extracellular domain)CD27 (Cluster of Differentiation 27)CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)CD70 (Cluster of Differentiation 70)CLEC12A
Beyond the preview
Go deeper on CLL-1-CD70 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLL-1-CD70 CAR-T.